Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polydexa
- Development stage
- Unknown
- Lead developer
- Bouchara-Recordati
- Modality
- Small Molecules, Peptides
- Administration
- Intranasal, Otic
01
Overview
Polydexa is a fixed-dose combination pharmaceutical preparation containing the synthetic glucocorticoid dexamethasone, the aminoglycoside antibiotic neomycin, and the polypeptide antibiotic polymyxin B. It is primarily formulated as ear drops (otic solution) for the local treatment of external otitis (otitis externa) and acute otitis media in patients with an intact tympanic membrane. The combination provides dual therapeutic action: dexamethasone exerts a potent anti-inflammatory effect to reduce swelling, redness, and itching, while neomycin and polymyxin B act synergistically to provide broad-spectrum antibacterial coverage against Gram-positive and Gram-negative pathogens. A nasal spray variant, Polydexa with Phenylephrine, is also available for the treatment of infectious and inflammatory diseases of the nasal cavity and paranasal sinuses. Polydexa was originally developed by Laboratoires Bouchara (now Bouchara-Recordati) and is marketed globally.
- Brand names
- PolydexaPolydexa with Phenylephrine
- Other names
- dexamethasone + neomycin + polymyxin Bdexamethasone, neomycin, and polymyxin Bdexamethasone/neomycin/polymyxin B
02
Targets
Bacterial RibosomeGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Polydexa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polydexa.